Introduction
PCBs are persistent, synthetic, lipophilic, toxic chemicals that are currently ubiquitous environmental contaminants (1) . Their manufacture and distribution increased markedly beginning about 1929. Based on laboratory, wildlife, and some human studies, their toxicity was later appreciated, and PCBs were banned from production and new use in the United States and in other countries (2) . Human health studies have been hampered by difficulty in estimating actual intake as distinguished from potential exposure and in characterization and quantification of isomers. Levels ofthe toxic coplanar, mono-ortho-substituted, and di-ortho-substituted PCB congeners have not been reported in human tissues from the general population or exposed persons from the United States until recently.
In the United States, packed column chromatography ofblood or fat, followed by matching of peaks containing several PCB isomers, with patterns reported as commercial PCB mixtures, such as Aroclor 1242 or Aroclor 1260, was the usual approach used for measurement and reporting of PCBs in human tissue. Frequently, the detection limits even for this total value were quite high, for example, 5-15 ppb in human serum at some laboratories, which may be above the mean level for the general population.
Packed-column approaches common in the United States are being replaced by capillary-column methods with the use ofPCB standards, which have recently become widely available, to aid in identification of peaks. It is only recently that values for individual congeners have been reported by a small number of laboratories, very few of which are in the United States.
Since the 209 possible PCB congeners vary considerably in toxicity and in persistence in humans, failure to report individual congeners presents at least two problems. In some cases, total levels found in a potentially exposed person after an incident may be within the "normal" range for a given population, but because levels before exposure were not known, it is impossible to determine whether exposure and increase in body burden did occur. This problem might be avoided if congeners with longer half-lives were reported and found to be elevated. Further, it is now known that certain PCB mixtures and specific PCB congeners exert a neurotoxic action (3) (4) (5) (6) (7) (8) (9) . Ifthe individual congeners are not identified and quantified, it is not possible to determine if there is an increase in body burden ofthose PCBs that may be of concern for a given health outcome.
In health studies, whether epidemiological or clinical, determination of dose from exposure to PCBs in cases as well as in controls is essential. If all or most ofthe toxic PCBs present are not measured, the exposure estimates are far less accurate than would otherwise be the case. Ifone measures dioxins and dibenzofurans in human tissues, but not the dioxinlike coplanar PCBs and mono-ortho-substituted PCBs, then only a portion of the dioxinlike toxic chemicals are being measured. With measurement only of the dioxins and dibenzofurans in human tissue, clinical and epidemiological studies may well misclassify exposure in cases and controls. This may, in part, explain the conflicting human health studies regarding these chemicals. We recently began to measure coplanar, mono-ortho and di-orthosubstituted PCBs when it was suggested that measurement of dioxins and dibenzofurans alone resulted in a misclassification of total dioxin toxicity; this in turn could lead to errors in epidemiology studies.
In this paper, we review selected case histories from our recent work measuring human tissue PCB levels, on occasion in conjunction with dioxin measurements, as it has evolved over the past decade. The studies were performed either to attempt to determine whether intake occurred after potential exposure to PCBs, polychlorinated dibenzodioxins, or polychlorinated dibenzofurans or to determine baseline levels for a population. Despite the now preferred congener-specific methods, the older packed-column separation and measurement of PCBs has proved useful in some cases for documenting actual intake following a potential exposure. For historical reasons, this will be illustrated also.
Methods
Human blood, plasma, or tissue was placed in chemically clean containers and frozen at temperatures ofat least -20 'C until analyzed. The analytic techniques are referenced and will not be repeated here (10) (11) (12) (13) (14) .
Results and Discussion
Yusho Rice Oil Poisoning, Japan, 1968
To illustrate current findings from the Yusho rice oil poisoning incident of Fukuoka, Japan, where PCBs, PCDFs, and PCDDs were ingested, Table 1 reports a total of 6.9 ppb on a wet-weight basis for the Yusho patients blood in this series as compared with 1.6 for the controls (15) (16) (17) Figure 1 graphically depicts mean PCB serum levels for the selected tetra through heptachlorinated PCBs in blood of 11 patients as compared to the control blood from the general population. The levels vary by congener, although the total PCB level is 6.9 ppb for the Yusho patients and 1.6 for the Japanese controls, by the method used. For specific isomers, such as 2,4,5,3',4 '-PeCB, levels are similar at this time period, at 0.11 and 0.14 ppb. As previously noted, the blood specimens from these Yusho victims were collected 21 years after exposure which occurred in 1968, documenting the persistence in human tissue of certain PCB congeners following high exposures.
Guam PCB Transformer Incident, 1987 (30) .
average value is 1 1.2 for the potentially exposed workers in this the ten lowest levels found in a second series of200 potentially series. This lower B/C ratio is believed to be due to induction of exposed Guam workers. The total levels were obtained by sumhepatic enzymes capable of metabolizing the B congener, 2,4, ming the individual congener values. Clearly, even without hav-5,3 ',4 '-penta-CB, more readily than the C congener, 2,4,5,2', ing previous general population PCB levels on Guam, the 10 4 ',5 '-hexa-CB.
high levels are markedly above that of others potentially ex- Figure 2 summarizes PCB findings from the same incident, posed, which is consistent with exposure to and intake of PCBs using different analytic techniques (14) . Because Guam is a in some of the potentially exposed workers. remote South Pacific island, no previous data were available on general population levels of PCBs, so the highest and lowest Binghamton, New York, PCB Transformer PCB levels from potentially exposed workers are compared. As Fire Incident, 1981 noted in the previous Guam series in Table 2 , one worker in a series of nine showed elevation of specific PCB congeners and Figure 3 shows a different approach to the use ofblood serum total PCBs. Here, the ten highest PCB levels are compared with PCB measurement to establish actual exposure or increased body (18, 19) .
U. S. Capacitor Explosion and Exposure of Children
Tissue PCB levels from another incident are shown in Figure  4 . This incident involved a PCB capacitor explosion in the United States after which metal and insulator wrapping, impregnated with PCBs, fell to the ground (11) . A group of children played with these attractive wrappings and some experienced various acute health effects. One developed an allergic reaction and was treated for respiratory distress and ocular discharge at a hospital emergency room. Several others developed rashes and pruritus. Because the incident involved a capacitor rather than a transformer, lower chlorinated biphenyls predominated in the mixture. In Figure 4 , data are presented for three groups ofchildren; those with direct exposure (skin contact), those with indirect exposure (contact with direct-contact children at time ofexposure), and those with no exposure (i.e., siblings living in the same household or friends). The PCBs are categorized as higher chlorinated and lower chlorinated depending on their retention compared to DDT. Children with no exposure were tested once and found to have 1.9 ppb of lower chlorinated PCBs (LPCBs) and 2.4 ppb of higher chlorinated PCBs (HPCBs). For four children with direct exposure, the LPCBs averaged 12.9 in August, 9 in January, and 6.3 ppb in July, whereas the HPCBs were found initially to be only 2.6 ppb, 2.1 in January, and finally 1.5 ppb in July. The different levels and response over time to the LPCBs is striking in the directly exposed group of children.
PCB Congeners in Human Tissues
PCB levels are usually reported from fat tissue or blood specimens. It is useful to recognize that these levels reflect body burden and are related to levels in various target organs of concern, but are not necessarily identical in level to these organs on either a wet weight or lipid basis. industrialized north and the more-industrialized south; Cambodia is a nonindustrial country; and Thailand is a rural, developing country beginning the process of industrialization (20) (21) (22) Of considerable interest are recent reports ofthe toxic coplanar PCB congeners in human tissue at relatively high levels compared to dioxins and dibenzofurans (24) (25) (26) (27) . We were concerned that by reporting dioxin and dibenzofuran congeners and PCBs other than coplanar and mono-ortho-substituted PCBs in human tissue, we might be underestimating total dioxinlike chemicals and their toxicity in humans from industrial countries. We were also concerned that this lack of information might be producing misleading estimates of such toxicity, thus causing major methodological problems in human health studies concerning dioxin, or, for that matter, PCB exposure. Therefore, we included all measurable PCBs in a Michigan Agent Orange Blood Dioxin Pilot Study in addition to the dioxins and dibenzofurans. There is no reason to suppose that the 50 U.S. Vietnam veterans in this study would have any special exposure to PCBs or would differ from other Michigan residents or a laboratory pooled blood control sample from Kansas City, Missouri, residents. Of concern for the Vietnam veterans was elevated 2,3,7,8-TCDD from Agent Orange exposure (20 years previously) and total dioxin toxicity. Our findings are presented in Table 4 . We measured the dioxins, dibenzofurans, non-ortho-coplanar PCBs,3,4,3 4'-TCB (PCB for total dioxins and dibenzofurans to total measured PCBS.
Using the estimated PCB toxic equivalency factors proposed by Safe (18) 3-52 %, among this group where some persons had elevated TCDD and others did not. The dibenzofurans' percent contribution ranges from 3-20%, and non-ortho PCBs contribute between 4 and 15 %, but the di-ortho-substituted PCBs, which contributed the most to the measured levels, contributed only 2-5 % to the total TEq. Figure 6 summarizes and graphically presents the total TEq values for nineteen of the Michigan veterans and also the Kansas City, Missouri, pooled blood bank (n=5) whole-blood laboratory controls, as well as the mean, minimum, and maximum levels. Figure 6A shows the total PCDD/F TEq levels ranging from 12 to 150, with a mean of 44. Figure 6B presents the levels for the PCBs dioxin toxic equivalents (TEq). The Missouri controls have a mean level of46, and the values for the veterans (mean, 67) range from 35 to 290, the latter value documenting an exposure from an unknown source. From Figure 6C it is possible to visualize a ratio ofalmost 1:2 for PCDD/Fs to PCBs in the total TEq. With these findings, it is probable that human health studies concerning these previously unmeasured, highly toxic PCBs may be making serious misclassification errors as to exposure ofcases and controls. Clearly, using current estimates of dioxin TEqs, total dioxin toxicity is considerably higher in the tissues of persons from the general population than was previously thought to be the case.
Conclusion
In the 60 years since large-scale PCB production began, PCBs have become ofconcern because oftheir toxicity and the amount synthesized. Several analytic approaches have been used to measure PCBs in human tissue. Each has its uses and its drawbacks. Analysis by packed column for total PCBs, presented as an Aroclor mixture approximation, is relatively inexpensive, at $75-$125 per analysis, and only 5-10 mL of whole blood or serum is required. Measurement of individual congeners usually costs $300-$600 per analysis. If coplanar PCBs, orthosubstituted PCBs, and dioxins and dibenzofurans are measured, cost is usually between $1,500 and $3,000 per analysis. PCDD/F analysis in human tissues usually costs $1,500-$2,500 per analysis, and only about one dozen laboratories qualified in a recent WHO interlaboratory PCDD/F and PCB blood and milk validation study. Several other highly competent laboratories exist, but worldwide capacity is quite limited at present. Health insurance usually does not pay for such monitoring because it is currently considered experimental or a research tool. Workers' compensation programs also usually do not pay for PCB blood, fat or milk analyses, even when exposure at work and subsequent illness is in question.
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